How Is TDM-105795 Used in Hair-Related Products, and Is It Being Explored as a Topical Treatment, an Oral Option, or Both?

When a compound such as TDM-105795 begins circulating in hair‑loss discussions, the responsible approach is to examine what is actually documented rather than what is implied. The short answer from the public record is that TDM-105795 is not used in any hair‑related product you can buy: it is an unapproved investigational compound. It has, however, been studied — as a topical solution applied to the scalp, in three completed company‑run trials registered on ClinicalTrials.gov. No oral formulation has been registered.

What the public record establishes about TDM-105795

TDM-105795 is being developed by Technoderma Medicines. Three trials in men with androgenetic alopecia are listed on the U.S. trial registry, and all three used a topical solution applied to the scalp:

• NCT04913519 — Phase 1, TDM-105795 topical solution, 30 participants, started April 2021, completed.
• NCT05244980 — Phase 1, 32 participants, started February 2022, completed.
• NCT05802173 — Phase 2, 71 participants, started March 2023, completed January 2024. Randomized, double‑blind, vehicle‑controlled, three parallel groups: 0.0025% solution, 0.02% solution, or vehicle, applied once daily to thinning and bald areas of the scalp for 16 weeks.

It is equally important to say what is not there. TDM-105795 is not an approved medicine anywhere. It does not appear as an approved product in FDA drug listings, it is not registered as a cosmetic ingredient, and — at the time of writing — a PubMed search returns no peer‑reviewed publication indexed under the compound name. The results that exist are the registry postings and the sponsor's own press releases, which are company statements rather than independent, peer‑reviewed evidence.

How hair‑loss treatments are normally studied

To read that record properly it helps to know how hair‑loss treatments are usually developed. Early research commonly begins with laboratory experiments using cultured cells or animal models, most often mice. These studies aim to determine whether a compound affects the hair growth cycle, which consists of the anagen phase, when hair actively grows, the catagen phase, when growth slows and follicles regress, and the telogen phase, when hair rests before shedding. Researchers evaluate results using standardized methods such as microscopic examination of hair follicles, measurement of hair shaft thickness, or photographic analysis over a defined period.

If results suggest a biological effect, researchers then decide how the compound should be delivered. A topical treatment is applied directly to the scalp and is designed to act locally, limiting how much of the substance enters the bloodstream. An oral treatment, by contrast, circulates throughout the body and therefore requires extensive safety testing due to the higher risk of systemic side effects. This distinction is not theoretical; it shapes the entire research pathway of a potential hair‑loss drug.

The topical evidence: what the Phase 2 trial actually measured

The Phase 2 study's primary measure was non‑vellus target area hair count — the number of terminal hairs in a marked one‑square‑centimetre patch of scalp — at week 16, alongside a seven‑point patient hair‑growth questionnaire. Secondary measures included hair width and hair darkness in the same area.

The results posted on the registry in November 2025 report a mean change in target‑area hair count at 16 weeks of about +20 hairs in the 0.0025% group, +22 hairs in the 0.02% group, and +14 hairs in the vehicle group. Two things follow. The active arms did move above vehicle. But the spread around those averages is large — comparable to or larger than the averages themselves in two of the three arms — the trial had 71 participants across three groups, ran only 16 weeks, and the registry posting carries no statistical analysis of the difference. The sponsor's press release describes the trial as demonstrating hair growth; that is a company characterisation of its own study, not an independent conclusion, and no peer‑reviewed report has yet been published for outside researchers to check.

So: there is real, registered topical research, and it is early. A 16‑week Phase 2 in 71 men is a signal to watch, not proof of a working treatment.

Is oral use being investigated?

On the public record, no. All three registered TDM-105795 studies are topical scalp applications. No oral dosing study for this compound appears on ClinicalTrials.gov, and no published toxicology or dose‑finding work for an oral version is indexed in PubMed. Oral hair‑loss treatments expose the entire body to the active compound and normally leave a registry or publication trail well before they reach patients; for TDM-105795, that trail does not exist.

Why forum discussion is not the same as evidence

Hair‑loss platforms and forums, including this one, frequently discuss emerging compounds. That discussion is useful for tracking what is in development, but it is not a substitute for primary data. Claims about TDM-105795 that do not name a trial, a number of participants, a duration and an outcome measure cannot be checked. Where this article gives numbers, they come from the trial registry entries listed below.

What is still unknown

Several things a reader would want to know are not yet answerable from the public record. There is no published peer‑reviewed report of any TDM-105795 trial. There is no data beyond 16 weeks, so durability of any effect is unknown. There is no long‑term safety data, and no head‑to‑head comparison with minoxidil or finasteride. There is no published data in women. And there is no approved product, so anything sold online under this name is not a regulated medicine and has not been shown to contain what it claims.

TDM-105795 is an experimental compound. It is not available as a medicine, its long‑term safety is unknown, and it should not be treated as a substitute for treatments that have been through full regulatory review. Talk to a doctor or pharmacist before starting, stopping or combining any hair‑loss treatment, and before using any unapproved research compound.

Evidence‑based answer

TDM-105795 is not used in any hair‑related product on the market, because it is not an approved medicine. It is being explored as a topical scalp treatment only — three completed registered trials, the largest a 71‑participant, 16‑week Phase 2 — with no oral programme on the public record. The registry results show higher average hair‑count gains in the active arms than on vehicle at 16 weeks, but with wide spread and no statistical analysis, so it is not known whether the difference is real; the results are not yet published in a peer‑reviewed journal.

References

Technoderma Medicines Inc. A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA) (NCT04913519). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04913519

Technoderma Medicines Inc. A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA) (NCT05244980). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05244980

Technoderma Medicines Inc. Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia (NCT05802173). ClinicalTrials.gov — protocol and posted results. https://clinicaltrials.gov/study/NCT05802173

Technoderma Medicines. (2023). Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial [company press release]. PR Newswire. https://www.prnewswire.com/news-releases/technoderma-medicines-initiates-tdm-105795-androgenetic-alopecia-phase-2-clinical-trial-301800212.html

Technoderma Medicines. (2024). Technoderma Medicines Phase 2 Clinical Trial of TDM-105795 Demonstrates Hair Growth in Androgenetic Alopecia [company press release]. PR Newswire. https://www.prnewswire.com/news-releases/technoderma-medicines-phase-2-clinical-trial-of-tdm-105795-demonstrates-hair-growth-in-androgenetic-alopecia-302052631.html